Amneal Stock Near Fair Value: Q1 Held Up, but the Upside Case Is No Longer Cheap

Amneal's rerating is already visible

Amneal is no longer an obvious hidden bargain. Its market value moved from $3.57B last November to about $5.06B by June 2026, so the easy rerating is likely behind it. At this point, the market is paying for more than a solid generics base; it is paying for consistent execution.

The latest results reinforced that shift. Amneal delivered Q2 revenue of $796.2 million and adjusted EPS of $0.30, a 30.3% beat, while lifting its full-year revenue midpoint to $3.15 billion. That kind of performance can support a stronger valuation, but it also reduces the margin for disappointment.

Q1 and Q2 both held up, which raises the bar

The operating bar has already been cleared. Amneal's Q1 net revenue of $723 million, $202 million adjusted EBITDA, and $0.27 adjusted diluted EPS set a strong tone. Q2 then helped show that the first quarter was not a one-off, with $796.2 million in revenue and adjusted EBITDA of $206.5 million.

That matters because repeated strong quarters do more for valuation than a single beat. If Amneal keeps converting launches and portfolio mix into reported results, the current valuation can be defended. If the streak stalls, the stock has less room to hide behind a multiple that already reflects confidence.

At roughly 34x earnings, fair value looks close to the market price

At a $5.32B market cap and about 34.33x P/E, Amneal is no longer priced like a name the market expects to simply improve incrementally. It is priced for a higher-quality earnings trajectory.

That is why the setup now looks more about fair value than deep discount. A company trading at that multiple can still move higher, but the path likely requires sustained EPS growth over several quarters, not just another beat-and-raise cycle.

What keeps the rerating alive

The next test is operational proof. The company's first quarter 2026 results and affirmed full-year guidance keep the discussion focused on whether management can turn a strong start into a full-year print that looks disciplined and repeatable.

The part of the story that still has traction is specific. Management tied its outlook to Specialty performance, led by CREXONT and the recent launch of BREKIYA autoinjector, along with a strong cadence of key launches in Affordable Medicines. If that mix keeps driving higher-quality growth, investors have a reason to stay engaged.

What would weaken the case

The thesis weakens if:

• Specialty momentum stops looking exceptional
• Launch contributions fail to show up in reported results
• Management falls short of the previously raised 2026 guidance range

With the stock still carrying about 34.33x P/E, the market may not reward a string of merely decent quarters for long. For now, Amneal looks closer to fair value than to an obvious bargain.